Gianpaolo Balzano1, Giovanni Capretti2, Giuditta Callea3, Elena Cantù3, Flavia Carle4, Raffaele Pezzilli5. 1. Unit of Pancreatic Surgery, San Raffaele Scientific Institute, Milan, Italy; Italian Association for the Study of Pancreas (AISP), Italy. Electronic address: balzano.gianpaolo@hsr.it. 2. Unit of Pancreatic Surgery, San Raffaele Scientific Institute, Milan, Italy; Italian Association for the Study of Pancreas (AISP), Italy. 3. Centre for Research on Health and Social Care Management (CERGAS), Università Commerciale Luigi Bocconi, Milan, Italy. 4. Directorate of Health Care Planning, Ministry of Health, Roma, Italy; Centre of Epidemiology, Biostatistics and Information Technology, Università Politecnica delle Marche, Ancona, Italy. 5. Italian Association for the Study of Pancreas (AISP), Italy; Pancreas Unit, Department of Digestive Diseases and Internal Medicine, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Abstract
BACKGROUND: According to current guidelines, pancreatic cancer patients should be strictly selected for surgery, either palliative or resective. METHODS: Population-based study, including all patients undergoing surgery for pancreatic cancer in Italy between 2010 and 2012. Hospitals were divided into five volume groups (quintiles), to search for differences among volume categories. RESULTS: There were 544 hospitals performing 10 936 pancreatic cancer operations. The probability of undergoing palliative/explorative surgery was inversely related to volume, being 24.4% in very high-volume hospitals and 62.5% in very low-volume centres (adjusted OR 5.175). Contrarily, the resection rate in patients without metastases decreased from 86.9% to 46.1% (adjusted OR 7.429). As for resections, the mortality of non-resective surgery was inversely related to volume (p < 0.001). Surprisingly, mortality of non-resective surgery was higher than that for resections (8.2% vs. 6.7%; p < 0.01). Approximately 9% of all resections were performed on patients with distant metastases, irrespective of hospital volume group. The excess cost for the National Health System from surgery overuse was estimated at 12.5 million euro. DISCUSSION: Discrepancies between guidelines on pancreatic cancer treatment and surgical practice were observed. An overuse of surgery was detected, with serious clinical and economic consequences.
BACKGROUND: According to current guidelines, pancreatic cancerpatients should be strictly selected for surgery, either palliative or resective. METHODS: Population-based study, including all patients undergoing surgery for pancreatic cancer in Italy between 2010 and 2012. Hospitals were divided into five volume groups (quintiles), to search for differences among volume categories. RESULTS: There were 544 hospitals performing 10 936 pancreatic cancer operations. The probability of undergoing palliative/explorative surgery was inversely related to volume, being 24.4% in very high-volume hospitals and 62.5% in very low-volume centres (adjusted OR 5.175). Contrarily, the resection rate in patients without metastases decreased from 86.9% to 46.1% (adjusted OR 7.429). As for resections, the mortality of non-resective surgery was inversely related to volume (p < 0.001). Surprisingly, mortality of non-resective surgery was higher than that for resections (8.2% vs. 6.7%; p < 0.01). Approximately 9% of all resections were performed on patients with distant metastases, irrespective of hospital volume group. The excess cost for the National Health System from surgery overuse was estimated at 12.5 million euro. DISCUSSION: Discrepancies between guidelines on pancreatic cancer treatment and surgical practice were observed. An overuse of surgery was detected, with serious clinical and economic consequences.
Authors: G A Gooiker; V E P P Lemmens; M G Besselink; O R Busch; B A Bonsing; I Q Molenaar; R A E M Tollenaar; I H J T de Hingh; M W J M Wouters Journal: Br J Surg Date: 2014-05-20 Impact factor: 6.939
Authors: R Yoshioka; H Yasunaga; K Hasegawa; H Horiguchi; K Fushimi; T Aoki; Y Sakamoto; Y Sugawara; N Kokudo Journal: Br J Surg Date: 2014-02-24 Impact factor: 6.939
Authors: Jeffrey M Sutton; Gregory C Wilson; Ian M Paquette; Koffi Wima; Dennis J Hanseman; R Cutler Quillin; Jeffrey J Sussman; Michael J Edwards; Syed A Ahmad; Shimul A Shah; Daniel E Abbott Journal: HPB (Oxford) Date: 2014-07-16 Impact factor: 3.647
Authors: Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia Journal: Lancet Oncol Date: 2013-12-05 Impact factor: 41.316
Authors: John M Lyons; Ami Karkar; Camilo C Correa-Gallego; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; William R Jarnagin; Murray F Brennan; Peter J Allen Journal: HPB (Oxford) Date: 2012-05-15 Impact factor: 3.647
Authors: Niamey P Wilson; Francis P Wilson; Mark Neuman; Andrew Epstein; Richard Bell; Katrina Armstrong; Kenric Murayama Journal: Am J Surg Date: 2013-12 Impact factor: 2.565
Authors: Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans Journal: Am J Cancer Res Date: 2022-02-15 Impact factor: 6.166
Authors: Lydia G M van der Geest; Casper H J van Eijck; Bas Groot Koerkamp; Valery E P P Lemmens; Olivier R Busch; Pauline A J Vissers; Johanna W Wilmink; Marc G Besselink Journal: Cancer Med Date: 2018-09-06 Impact factor: 4.452
Authors: M W Steen; L B van Rijssen; S Festen; O R Busch; B Groot Koerkamp; L G van der Geest; I H de Hingh; H C van Santvoort; M G Besselink; M F Gerhards Journal: BJS Open Date: 2020-08-25
Authors: Lauren M Rosati; Megan N Kummerlowe; Justin Poling; Amy Hacker-Prietz; Amol K Narang; Eun J Shin; Dung T Le; Elliot K Fishman; Ralph H Hruban; Stephen C Yang; Matthew J Weiss; Joseph M Herman Journal: Oncotarget Date: 2017-06-12